Study of ADCT-301 in Patients With Selected Advanced Solid Tumors


Study Number
73618
Phase
1
Age Group
Adult
Purpose

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Full Title

ADCT-301-103: A Phase 1b, Open-Label, Dose-Escalation and DoseExpansion Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine
(ADCT-301) as Monotherapy or in Combination in Patients With
Selected…

ClinicalTrials.Gov ID
NCT03621982

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.